Physician profile
Ari Zelig
NPI 1740555952
$231,717.61
in general payments reported to CMS, 2019-2025
31 companies · $27K in 2025
The $27K reported for 2025 was more than what 93% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $3,381 · 2021: $3,768 · 2022: $4,418 · 2023: $103K · 2024: $65K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $168K · Consulting Fee: $8,865 · Travel and Lodging: $8,857 · Food and Beverage: $8,250 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $168,145.00 |
| Consulting Fee | $8,865.00 |
| Travel and Lodging | $8,856.86 |
| Food and Beverage | $8,250.03 |
| Education | $132.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $152,745.42 | 2019-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Genentech USA, INC. | $31,837.76 | 2019-2025 | Xolair |
| Astrazeneca Pharmaceuticals LP | $27,878.56 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Novartis Pharmaceuticals Corporation | $8,120.44 | 2019-2025 | |
| Ars Pharmaceuticals Operations, INC. | $3,760.90 | 2025 | Neffy |
| Genzyme Corporation | $2,976.02 | 2019-2025 | |
| Genentech, INC. | $780.25 | 2019-2023 | Xolair |
| Regeneron Healthcare Solutions, INC. | $616.16 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $501.78 | 2020-2025 | Cuvitru, Hyqvia |
| Amgen INC. | $471.17 | 2021-2025 | Tezspire |
| Optinose US, INC. | $242.62 | 2019-2024 | |
| Octapharma USA, INC. | $229.14 | 2019-2022 | |
| Pfizer INC. | $205.43 | 2019-2025 | |
| Kaleo, INC. | $196.75 | 2019-2023 | Auvi-Q |
| Stryker Corporation | $175.95 | 2025 | Scopis Ent |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $150.18 | 2023-2025 | Ruconest |
| Grifols USA, LLC | $118.16 | 2019-2024 | Xembify |
| Sanofi-Aventis U.S. LLC | $98.99 | 2025 | |
| Shire North American Group INC | $90.71 | 2019 | |
| Csl Behring | $84.45 | 2019-2023 | Haegarda |
| Teva Pharmaceuticals USA, INC. | $73.71 | 2020 | |
| Hikma Pharmaceuticals USA | $73.65 | 2023-2024 | Ryaltris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.26 | 2019-2020 | |
| Biocryst US Sales Co., LLC | $51.63 | 2023-2024 | Orladeyo |
| Aerin Medical INC. | $51.30 | 2025 | |
| Aimmune Therapeutics, INC. | $25.34 | 2021 | |
| Organon LLC | $25.13 | 2025 | |
| Ionis Pharmaceuticals, INC. | $21.71 | 2025 | Dawnzera |
| Incyte Corporation | $19.87 | 2025 | Opzelura |
| Alk-Abello, INC | $17.48 | 2019 | |
| Abbvie INC. | $15.69 | 2023 | Rinvoq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ari Zelig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.